1. Home
  2. SHEN vs ABUS Comparison

SHEN vs ABUS Comparison

Compare SHEN & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SHEN
  • ABUS
  • Stock Information
  • Founded
  • SHEN 1902
  • ABUS 2005
  • Country
  • SHEN United States
  • ABUS United States
  • Employees
  • SHEN N/A
  • ABUS N/A
  • Industry
  • SHEN Telecommunications Equipment
  • ABUS Biotechnology: Pharmaceutical Preparations
  • Sector
  • SHEN Telecommunications
  • ABUS Health Care
  • Exchange
  • SHEN Nasdaq
  • ABUS Nasdaq
  • Market Cap
  • SHEN 726.3M
  • ABUS 711.2M
  • IPO Year
  • SHEN N/A
  • ABUS N/A
  • Fundamental
  • Price
  • SHEN $13.36
  • ABUS $4.30
  • Analyst Decision
  • SHEN Strong Buy
  • ABUS Strong Buy
  • Analyst Count
  • SHEN 1
  • ABUS 2
  • Target Price
  • SHEN $26.00
  • ABUS $5.00
  • AVG Volume (30 Days)
  • SHEN 300.2K
  • ABUS 1.3M
  • Earning Date
  • SHEN 11-06-2025
  • ABUS 11-05-2025
  • Dividend Yield
  • SHEN 0.76%
  • ABUS N/A
  • EPS Growth
  • SHEN N/A
  • ABUS N/A
  • EPS
  • SHEN N/A
  • ABUS N/A
  • Revenue
  • SHEN $349,477,000.00
  • ABUS $15,416,000.00
  • Revenue This Year
  • SHEN $11.97
  • ABUS $138.02
  • Revenue Next Year
  • SHEN $9.07
  • ABUS N/A
  • P/E Ratio
  • SHEN N/A
  • ABUS N/A
  • Revenue Growth
  • SHEN 20.36
  • ABUS 53.23
  • 52 Week Low
  • SHEN $9.77
  • ABUS $2.71
  • 52 Week High
  • SHEN $16.28
  • ABUS $5.10
  • Technical
  • Relative Strength Index (RSI)
  • SHEN 47.70
  • ABUS 52.30
  • Support Level
  • SHEN $13.02
  • ABUS $4.29
  • Resistance Level
  • SHEN $13.90
  • ABUS $4.66
  • Average True Range (ATR)
  • SHEN 0.40
  • ABUS 0.17
  • MACD
  • SHEN -0.02
  • ABUS -0.05
  • Stochastic Oscillator
  • SHEN 21.71
  • ABUS 30.93

About SHEN Shenandoah Telecommunications Co

Shenandoah Telecommunications Company, with its subsidiaries, provides various broadband communication products and services via its wireless, cable, fiber optic, and fixed wireless networks to customers in the Mid-Atlantic United States. The company operates through one business unit: Broadband. The broadband segment provides broadband Internet, video, and voice services to residential and commercial customers. The broadband segment generates the vast majority of the company's revenue, with the bulk of sales flowing from residential and small, and medium businesses within the broadband unit.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: